Adult neurogenesis is often studied by labeling new cells with the thymidine analog bromodeoxyuridine (BrdU) and using immunohistochemical methods for their visualization. Using this approach, considerable variability has been reported in the number of new cells produced in the dentate gyrus of adult rodents. We examined whether immunohistochemical methods, including BrdU antibodies from different vendors (Vector, BD, Roche, Dako, Novocastra, and Accurate) and DNA denaturation pretreatments alter the quantitative and qualitative patterns of BrdU labeling. We also compared the sensitivity and specificity of BrdU with two other thymidine analogs, iododeoxyuridine (IdU) and chlorodeoxyuridine (CldU). We found that the number of BrdU-labeled cells in the dentate gyrus of adult rats was dependent on the BrdU antibody used but was unrelated to differences in antibody penetration. Even at a higher concentration, some antibodies (Vector and Novocastra) stained fewer cells. A sensitive BrdU antibody (BD) was specific for dividing cells; all BrdU-labeled cells stained for Ki67, an endogenous marker of cell proliferation. We also observed that DNA denaturation pretreatments affected the number of BrdU-labeled cells and staining intensity for a marker of neuronal differentiation, NeuN. Finally, we found that IdU and CldU, when used at molarities comparable to those that label the maximal number of cells with BrdU, are less sensitive. These data suggest that antibody and thymidine analog selection, as well as the staining procedure employed, can affect the number of newly generated neurons detected in the adult brain, thus providing a potential explanation for some of the variability in the adult neurogenesis literature. J. Comp. 
MATERIALS AND METHODS Animals
For all experiments, adult male Sprague-Dawley rats (8 -10 weeks of age) were used (Taconic Farms, Germantown, NY). Rats were acclimated to the colony for at least 5 days prior to injection with BrdU, IdU, or CldU. Rats were group housed (2-3/cage), provided with unlimited access to food and water, and maintained on a reverse 12:12-hour light-dark cycle with lights on at 19:00 hours. All procedures were conducted in accordance with Princeton University AALAC and The National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Preparation and injection of thymidine analogs
The dose of BrdU used for all experiments was 200 mg/kg. This dose was selected because it labels the maximal number of cells in the dentate gyrus (Cameron and McKay, 2001 ). For purposes of comparison, IdU and CldU doses were equimolar to the BrdU dose. Solutions of BrdU (Sigma-Aldrich, Milwaukee, WI, cat. no. B5002, lot no. 076K1307) were prepared in sterile saline with 0.007 M NaOH at 20 mg/ml. IdU and CldU were less soluble than BrdU and, at the high doses used for this study, required dilution in a larger volume. IdU (MP Biomedicals, Irvine, CA, cat. no. 100357, lot no. 2742J) was prepared at 6 mg/ml and CldU (Sigma-Aldrich, cat. no. C6891, lot no. 106K1306) at 10 mg/ml, both in sterile saline with 0.007 M NaOH. The pH of all thymidine analog solutions was approximately 7.0.
Rats (n ‫؍‬ 6/group) were injected i.p. at approximately 13:00 hours with one of the thymidine analogs and perfused after a 2-hour survival time. An additional group of rats (n ‫؍‬ 6) was given BrdU injections on the same day and time but perfused after a 3-week survival time.
Histological procedures
Rats were anesthetized with an overdose of sodium pentobarbital and transcardially perfused with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.5). Brains were dissected from the skulls and postfixed for at least 2 days. Then 40-m-thick coronal sections throughout the entire rostrocaudal extent of the dentate gyrus were cut with a Vibratome from half brains into a bath of 0.1 M phosphate-buffered saline (PBS; pH 7.5). Each immunohistochemical reaction was performed simultaneously from all rats within a given experiment to maximize the reliability of comparison across groups.
Immunoperoxidase staining for
BrdU, CldU, and IdU A 1:12 series of sections from rats sacrificed at the 2-hour (BrdU, IdU, or CldU) or 3-week (BrdU) postinjection survival times was mounted onto glass slides and allowed to dry overnight. For pretreatment, 0.1 M citric acid (pH 6.0) was microwaved (GE, model no. JEM25GY001) at power level 10 for ϳ3 minutes. Slides were then placed into the heated citric acid, microwaved for 5 minutes at power level 2, removed from the microwave, and allowed to cool for 20 minutes. Slides were then rinsed 3X in PBS, incubated in trypsin for 10 minutes, rinsed, denatured in 2 N HCl/PBS for 30 minutes, and rinsed again. For BrdU staining, slides were incubated overnight at 4°C in one of the following antibodies (technical information for each one was provided by the manufacturer): 
Immunofluorescent co-labeling of BrdU and Ki67
Free-floating 40-m-thick sections from rats sacrificed at the 2-hour time point were rinsed 3X in TBS, pretreated with 2 N HCl/TBS for 30 minutes, rinsed, and then incubated at 4°C in rabbit polyclonal anti-Ki67/TBS (1:500; Novocastra Vision BioSystems, cat. no. NCLKi67p, lot no. 301114) and mouse monoclonal anti-BrdU/TBS (1:200; BD) with 0.5% Tween-20. The rabbit polyclonal anti-Ki67 antibody was generated by using prokaryotic recombinant fusion protein corresponding to a 1,086-bp Ki67 motif containing cDNA (manufacturer's technical information). A double band at 245-395 kDa is detected by Western blot analysis (Key et al., 1993) . Specific staining of dividing cells in the adult rat dentate gyrus by this antibody has been demonstrated previously (Dayer et al., 2003) . Following overnight incubation, sections were rinsed and incubated for 1 hour in the dark with goat anti-rabbit Alexa 488/TBS (1:250; Invitrogen Molecular Probes, Carlsbad, CA, cat. no. A11034, lot no. 51726A) and goat anti-mouse Alexa 568/TBS (1:250; Invitrogen Molecular Probes, cat. no. A11031, lot no. 39053A). Sections were rinsed, mounted onto glass slides, dried for at least 2 hours in the dark, and coverslipped with glycerol/TBS (3:1). As a control, brain sections from a rat that did not receive a BrdU injection was processed as described above.
Immunofluorescent labeling of NeuN
Sections (40 m thick) from rats sacrificed at the 3-week time point were rinsed 3X in TBS and then subjected to one of the following pretreatments: 
Data analysis
Slides were coded prior to data collection. The code was broken after the analysis of each experiment was complete.
BrdU, IdU, and CldU peroxidase analysis
The numbers of BrdU-, IdU-, or CldU-labeled cells on every 12th unilateral section throughout the entire rostrocaudal extent of the dentate gyrus (granule cell layer, subgranular zone, and hilus) were counted at 1,000؋ with an Olympus BX-50 light microscope by using a modified version of the optical fractionator method ( 
Antibody penetration analysis
Analyses of antibody penetration were performed by using the z-axis encoder on an Olympus BX-60 microscope attached to a computer equipped with StereoInvestigator software (MicroBrightField, Williston, VT). Section thickness and depth of labeling penetration (minimum and maximum) from the surface of the section were measured for all labeled cells in the granule cell layer and subgranular zone at 1,000؋. Cells that had a maximum depth penetration greater than half of the section thickness were also quantified in order to determine the percentage of labeled cells that penetrated to the center of the section.
BrdU and Ki67 immunofluorescent analysis
Analyses were done by using the 40؋ objective on a Zeiss Axiovert confocal microscope (Zeiss, Oberkochen, Germany) with Argon 458/488 and HeNe 543 lasers. A sequence configuration to scan each channel separately was employed in order to avoid cross-talk between fluorescent labels. For each brain, the percentage of Ki67-labeled cells in the dentate gyrus (granule cell layer and subgranular zone) that expressed BrdU was determined from 40 -50 randomly selected Ki67-labeled cells. In addition, the percentage of BrdU-labeled cells in the dentate gyrus that expressed Ki67 was determined from 8 -40 randomly selected BrdU-labeled cells per brain. For both analyses, optical stacks of 1-m-thick sections were obtained through putatively double-labeled cells. To verify double-labeling throughout their extent, cells were examined in orthogonal planes. Confocal images were acquired and stacked by using Zeiss 510LSM software, cropped, adjusted for contrast by using Adobe Photoshop 7.0, and then resized and arranged in Canvas 8.
NeuN immunofluorescent analysis
Optical sections (1 m thick) were scanned from the dentate gyrus by using the 40؋ objective on a confocal microscope with an Argon laser and Zeiss 510LSM software. Ten frames were obtained per rat per pretreatment condition, while holding the scanning parameters constant. Outlines of all NeuN-stained cell bodies in the scans were traced by using the measurement tool in the LSM software, and the mean intensity for each cell body was determined (0 -255 grayscale). The outline was then moved to an adjacent region void of any NeuN-positive cell bodies, and a background optical intensity measure was recorded. Every labeled cell was analyzed in this manner. Signal was defined as the mean intensity value for the cell bodies. Background was defined as the mean intensity value for the regions containing no stained cell bodies. The signal/noise ratio was calculated according to the following formula: (Signal ؊ Background)/Standard Deviation of the Background. Fluorescent images were acquired by using the LSM software, cropped in Adobe Photoshop 7.0, and then resized and arranged in Canvas 8. No other digital manipulations were employed. rats perfused 2 hours after BrdU injection and found large differences across groups (F (2,15) ‫؍‬ 75.81, P < 0.0001; Fig.  1A ). BrdU antibodies from BD and Roche labeled more cells than Vector (P < 0.001 for each post hoc comparison), with no difference observed between BD and Roche. In a second comparison, we extended our analysis to include three additional BrdU antibodies (Dako, Novocastra, and Accurate), again by using a 2-hour post-BrdU survival time. For comparison, we also included the BD antibody. Again, we observed differences in the number of BrdU-labeled cells in the dentate gyrus depending on the BrdU antibody used (F (3,20) ‫؍‬ 6.17, P < 0.005; Fig. 1B) . Novocastra labeled the fewest number of cells compared with the other antibodies (P < 0.05 for each post hoc comparison), which did not differ from one another.
To address the possibility that the differences in the number of BrdU-labeled cells is due to differential permeability of antibodies into slide-mounted sections, we assessed whether a high staining (BD) and a low staining (Vector) antibody penetrate throughout the section thickness equally. For both antibodies, labeled cells were distributed throughout the section, with the majority of labeling (ϳ80%) found in the center of the ϳ15-m section height. There was no difference in the Fig. 1A ). Because there is considerable collapse when sections are mounted on slides, dried, processed for immunohistochemical staining, counterstained, and dehydrated, it may be difficult to detect complete label penetration. Thus we performed an additional analysis on slide-mounted sections that were stained by using peroxidase methods and coverslipped with glycerol/PBS. Without the counterstain and dehydration steps, section collapse was less, with a final section thickness of ϳ25 m. We again found no differences in antibody penetration (minimum: t 10 ‫؍‬ 0.35, P > 0.05; maximum: t 10 ‫؍‬ 0.33, P > 0.05) between BD and Vector antibodies ( Supplementary  Fig. 1B) , with the majority (ϳ80%) of labeling evident in the center of the section. These data suggest that variations in the number of BrdU-labeled cells are likely due to differences in antibody sensitivity rather than antibody permeability.
To assess whether these differences were specific to a short post-BrdU injection survival time, we compared all six BrdU antibodies on tissue from rats injected with BrdU and perfused after 3 weeks. Again, we found large differences in the number of BrdU-labeled cells in the dentate gyrus across groups (F (5,30) ‫؍‬ 8.01, P < 0.0001; Fig. 1C ). Vector and Novocastra labeled the fewest cells compared with all other antibodies (P < 0.05 for each post hoc comparison). BD, Roche, Dako, and Accurate antibodies stained more cells in the dentate gyrus and did not differ significantly from each other. Qualitatively, labeling intensity in the dentate gyrus was greatest in tissue stained with antibodies that labeled the most cells ( Fig. 2; Supplementary Fig. 2 ). BrdU-labeled cells could be visualized at a total magnification of 100؋ for BD, Dako, Accurate, and Roche, whereas Vector and Novocastra required visualization using at least 400؋. Staining was not observed in the dentate gyrus with any of the antibodies on tissue from a rat that did not receive a BrdU injection.
Similar differences were observed in the number of BrdUlabeled cells in the SVZ across antibodies following a 2-hour post-BrdU survival time. Vector labeled the fewest cells compared with BD and Roche (F (2,15) ‫؍‬ 6.02, P < 0.01; Supplementary Fig. 3A) . In a second comparison, Novocastra labeled the fewest cells (F (3,20) ‫؍‬ 3.43, P < 0.05; Supplementary Fig.  3B ), but differed significantly only from Dako. 
B), H (applies to C-H), K (applies to I-K), and P (applies to L-P).

Sensitive BrdU antibodies are specific
To rule out the possibility that BrdU antibodies that label a high number of cells do so nonspecifically, we evaluated the specificity of a high-staining BrdU antibody (BD). Tissue from rats injected with BrdU followed by a 2-hour survival time was co-labeled with Ki67. Because Ki67 is an endogenous marker expressed during most phases of the cell cycle including S-phase (Kee et al., 2002; Eisch and Mandyam, 2007), all BrdU-labeled cells should co-express Ki67. However, not all Ki67 positive cells should co-express BrdU because BrdU only labels cells undergoing DNA synthesis. Indeed, we found that 100% of the BrdU-labeled cells in the dentate gyrus stained for Ki67, whereas only 47.8 ؎ 8.1% of the Ki67-labeled cells stained for BrdU (Fig. 2I-K) . Tissue from a rat that did not receive a BrdU injection showed Ki67, but not BrdU, labeling. These data suggest that the high-staining BD antibody specifically labels cells that are in S-phase at the time of the BrdU injection.
Less sensitive antibodies are not made equally sensitive by increasing their concentration
We examined whether the less sensitive BrdU antibodies (Vector and Novocastra) could be made more sensitive by increasing their concentration from 1:200 to 1:100. We also assessed whether the Dako antibody, which labels a large number of new cells at 1:200 (Fig. 1) , would label even more cells with an increased concentration of 1:100. We found that Dako at 1:100 did not label more cells in the dentate gyrus or SVZ than at 1:200 (dentate gyrus: compare Fig. 3 with Fig. 1 ; SVZ: compare Supplementary Fig. 4 with Supplementary Fig.  3) . However, at both the 2-hour (F (2,15) ‫؍‬ 4.72, P < 0.05; We also examined whether pretreatment methods impact phenotypic assessment of newborn cells by calculating a signal/noise ratio for immunofluorescence staining of the mature neuronal marker NeuN. Compared with tissue stained for NeuN using the HCl alone protocol, the signal/noise ratio was substantially reduced when HCl ؉ formamide or steam heating pretreatment methods were used (F (2,15) ‫؍‬ 8.83, P < 0.005; Fig. 4B ). Qualitatively, HCl ؉ formamide and steam heating were variable in their NeuN staining patterns-some sections had high background, whereas others had no nuclear staining ( Fig. 2L-P) . Overall, BrdU-labeled cells were more abundant in the dentate gyrus (F (2,26) ‫؍‬ 55.06; P < 0.0001; Fig. 5) and SVZ (F (2,26) ‫؍‬ 25.73, P < 0.0001; Supplementary Fig. 6 ) than either IdU-or CldU-labeled cells, suggesting that these thymidine analogs are not labeling S-phase cells with equal probability. Moreover, the detection of IdU and CldU was not specific to the antibodies we tested for the dentate gyrus (F (2,26) ‫؍‬ 34.10, P < 0.0001) and SVZ (F (2,26) ‫؍‬ 11.64, P< 0.0005). Although BD detected more IdU-labeled cells than Accurate (P < 0.0001), some IdU-labeled cells were detected with the Accurate antibody. Also, although Accurate detected more CldU-labeled cells than BD (P < 0.05), a substantial number of CldU-labeled cells were detected with the BD antibody.
Denaturation methods affect the number of BrdU-labeled cells and staining for NeuN
The thymidine analogs IdU and
DISCUSSION
These results demonstrate that commonly used BrdU antibodies do not label an equivalent number of cells. BrdU antibodies from Vector and Novocastra stained fewer cells in both the dentate gyrus and SVZ than BD, Roche, Dako, and Accu- Overall, BrdU-labeled cells in the dentate gyrus were more abundant than either IdU-or CldU-labeled cells (**, P < 0.05), suggesting that these thymidine analogs are not labeling cells undergoing S-phase with equal probability. Also, BrdU antibodies did not label IdU or CldU with specificity. Although BD detected more IdU-labeled cells than Accurate, some IdU-positive cells were found with the Accurate antibody. In addition, both BD and Accurate detected a substantial number of CldU-labeled cells. Bars represent mean ؎ SEM. *, P < 0.05. rate antibodies. Antibody penetration was similar for a low (Vector) and a high (BD) staining antibody, suggesting that variations in the number of BrdU-labeled cells are likely due to differences in antibody sensitivity rather than antibody permeability. The differences in the number of BrdU-labeled cells across antibodies were not eliminated by increasing the concentration of the less sensitive antibodies. Moreover, a highstaining antibody (BD) did not label nonspecifically, because all BrdU-labeled cells expressed Ki67, an endogenous marker of proliferating cells. Additional variability in BrdU labeling occurred with different denaturation pretreatments: HCl alone and HCl ؉ formamide stained more cells in the dentate gyrus than steam heating. Pretreatments also differentially affected immunofluorescent staining for the mature neuronal marker, NeuN-greater staining was observed with HCl-alone pretreatment. Finally, labeling with the thymidine analogs IdU and CldU resulted in fewer stained cells compared with BrdU. Whereas both IdU and CldU labeled a comparable number of cells in the dentate gyrus and SVZ, each stained fewer cells than BrdU using sensitive antibodies. Moreover, labeling with IdU and CldU at molarities comparable to those used for staining the maximal number of BrdU-labeled cells yielded antibody cross-reactivity. Given that the present work utilized peroxidase staining and brightfield microscopy, additional work is needed to assess the extent to which these findings apply to fluorescence methods. Nonetheless, these data suggest that current methodologies for studying adult neurogenesis are not equally sensitive and in some cases can lack specificity.
BrdU antibodies
Antibody selection is an important issue (Saper and Sawchenko, 2003; Rhodes and Trimmer, 2007), which until now has not been examined with regard to adult neurogenesis. In this study, differences in the number of BrdU-labeled cells were detected in the dentate gyrus and SVZ depending on the antibody used. Because antibody permeability did not differ between a high (BD) and low (Vector) staining antibody, the differences we observed are likely a result of varied antibody sensitivity.
Vector and Novocastra were the least sensitive and stained the fewest cells. These antibodies, although from different suppliers, are generated from the same clone (85-2C8). Despite a similar origin, Novocastra generally stained more cells than Vector. Increasing the concentration from 1:200 to 1:100 rendered Novocastra, but not Vector, equivalently sensitive to the high-staining antibodies at the 2-hour post-BrdU survival time. At the 3-week survival time, Novocastra stained more cells than Vector at the 1:100 concentration; however, Novocastra still labeled fewer cells than the more sensitive BrdU antibodies. One possible explanation for staining differences between the 2-hour and 3-week survival times for Novocastra at 1:100 is that after a 2-hour survival, BrdU-labeled cells are easier to detect because cells that incorporated BrdU have not divided and thus diluted the label.
DNA denaturation pretreatments
BrdU antibodies recognize BrdU in single-stranded DNA (Gratzner, 1982; Vanderlaan and Thomas, 1985) , thus necessitating denaturation pretreatments before primary antibody incubation. To investigate whether pretreatments alter the number of BrdU-labeled cells, we compared three BrdU staining protocols. Two used HCl for denaturation (Cameron and McKay, 2001 ), but one also included high-temperature incubation in the solvent formamide (Kuhn et al., 1996) . The third protocol used steam heating for denaturation (Tang et al., 2007) . By using a sensitive and specific BrdU antibody (BD), we found that protocols using HCl yielded the highest number of BrdU-labeled cells in the dentate gyrus. Thus, combined use of less sensitive antibodies and suboptimal pretreatments would likely further degrade staining procedures, altering data qualitatively and quantitatively.
In addition to differences in staining, cell counting methods are also critical (Saper, 1996) and may influence the number of BrdU-labeled cells reported. Here, we used a modified optical fractionator method that is common in studies of adult neurogenesis ( (Coggeshall and Lekan, 1996) , it remains to be tested whether modified and strict stereological approaches produce similar outcomes. One way in which these different counting methods may yield inconsistent results in the numbers of BrdU-labeled cells is under conditions such as harsh pretreatments, which lead to differential cell loss from the surface of the tissue section (i.e., lost caps). However, this explanation is unlikely to account for the data presented here because we avoided counting cells in the outermost focal plane where lost caps are likely to be located.
In contrast to the dentate gyrus, the number of labeled cells in the SVZ was unaffected by different pretreatments. This regional difference in sensitivity may be related to variations in BrdU availability for uptake. Because of its location in the ventricles, as opposed to in the parenchyma, proliferating cells in the SVZ may have greater access to BrdU than those in the dentate gyrus. Even with histological procedures that reduce staining intensity, cells heavily labeled with BrdU are likely to remain detectable in the SVZ. However, these findings should not be used as evidence that multiple BrdU injections be employed to label cells heavily throughout the brain. The choice of injection protocol must be thoughtfully considered within the context of the questions addressed in a particular experiment (Christie and Cameron, 2006) . Pretreatments also affected NeuN immunofluorescent staining in the dentate gyrus. The signal/noise ratio of NeuN staining was highest for HCl alone and was substantially reduced with the other methods, suggesting that the assessment of a new cell phenotype is sensitive to pretreatment methods. It is likely, however, that methods diminishing NeuN staining reduce the probability that cells containing relatively less NeuN (i.e., immature cells) will be detectable. The extent to which this variable contributes to inconsistencies in reports of adult neurogenesis in regions outside of the dentate gyrus and SVZ remains unknown (Gould, 2007) 2009). Instead, the data presented here suggest that studies using IdU and CldU (even at high doses) underestimate the number of newborn cells. This effect is likely due to differences in the sensitivity of the analogs themselves, but could also be related to the sensitivity of the antibodies used to detect them.
IdU and CldU as alternatives to BrdU
Prior work examining lower doses of BrdU, IdU, and CldU found similar numbers of labeled cells in the SVZ across markers using fluorescence methods (Bauer and Patterson, 2005) . It is possible that at high doses, like those used here, IdU and CldU are not completely available for uptake by cells in S-phase, either because they remain somewhat insoluble or have saturated uptake mechanisms. Making relative comparisons may require lower doses to prevent cross-reactivity, which can also be eliminated by using BrdU antibodies at greater dilutions. Indeed, a study using lower doses of IdU and CldU, as well as less concentrated BrdU antibodies, reported no such cross-reactivity (Vega and Peterson, 2005) . Future studies should include controls injected with a single analog to examine nonspecific staining with BrdU antibodies and should assess whether each analog labels similar numbers of cells given identical experimental conditions.
Potential contribution of histology to variability in adult neurogenesis studies
Adult neurogenesis in the dentate gyrus was first reported in the 1960s but was not accepted for decades. Earlier evidence may have been discounted because it was reported to be a quantitatively minor process (Gross, 2000) . The original studies used 3 H-thymidine autoradiography on relatively thick tissue sections (Altman and Das 1965 , 1966 , 1967 , a method that underestimates the number of labeled cells (Gross, 2000) . The application of BrdU labeling provided further evidence that new cells in the dentate gyrus were neurons and that adult neurogenesis is robust, supporting the idea that the production of new neurons in the adult brain may be functionally relevant (Cameron and McKay, 2001 ).
The present report suggests that commonly used BrdU methods likely underestimate the number of new neurons, and furthermore emphasizes the need to standardize BrdU labeling procedures. It also raises the question of whether studies that use less sensitive antibodies, thymidine analogs, or suboptimal pretreatments remain useful when making relative comparisons across groups. Because histological procedures are usually standardized across studies within a laboratory and similarly applied among groups within an experiment, it is likely that degradation of staining would affect all groups equally. However, it is theoretically possible that a population of cells containing only a small amount of BrdU exists in a certain experimental group, perhaps because the manipulation slows entry into S-phase or enhances the survival of cells that underwent multiple divisions after labeling. In these instances, the most sensitive conditions may be necessary to stain this lightly labeled population and thus detect group differences. Although such scenarios may be uncommon, they are perhaps relevant when studies of similar design but varying histological methods produce inconsistent results. It is noteworthy that in many instances, relative group differences are preserved across a range of antibodies. 
